The rapid rise of glucagon-like peptide-1 receptor agonists, or GLP-1 RAs, is transforming the treatment of obesity—and exposing a problem that medicine has struggled to solve for decades. These drugs can reduce appetite, alter food-reward pathways and improve several cardiometabolic measures, including blood-glucose control and cardiovascular risk factors. Their popularity has surged across clinical practice, private health services and, increasingly, self-directed online markets. But a new commentary in BMC Medicine argues that the medication revolution will not deliver its full promise unless it is paired with sustained psychological, behavioral and social support. Brunna Boaventura of the Federal University of Santa Catarina in Brazil and Stuart W. Flint of the University of Leeds in the UK warn that prescribing medication without helping people build durable behavior-change skills could create a modern version of an old mistake: treating body weight as an isolated problem rather than as one part of a complex chronic disease.

The authors’ central message is not that lifestyle interventions should replace medication. Instead, they argue that obesity care must become genuinely multimodal, combining pharmacological treatment with structured behavioral support and, when appropriate, psychological, nutritional, medical and surgical care. The World Health Organization recognizes obesity as a chronic, relapsing disease, meaning that long-term management is often necessary even after substantial weight loss. Yet in routine healthcare, behavioral treatment is frequently reduced to brief advice—“eat better,” “exercise more” or “monitor your weight”—rather than delivered as a continuous clinical service. That implementation gap has several causes: many clinicians receive limited training in behavior-change techniques, referral routes to dietitians, psychologists and health coaches may be weak, reimbursement is often inadequate, and healthcare systems rarely account for the social and structural conditions that shape daily choices. The result is a mismatch between the biological complexity of obesity and the simplicity of the support many patients receive.

GLP-1 RAs make that mismatch more consequential because their benefits are closely tied to continued treatment and individual response. The drugs mimic or enhance signaling by hormones involved in appetite regulation and glucose metabolism. By activating GLP-1 receptors, they can slow gastric emptying, increase feelings of fullness and reduce food intake; their metabolic effects can also improve glycemic control. But these physiological changes do not automatically resolve the habits, routines, emotional triggers, social pressures or practical barriers that influence eating and physical activity. Nor do they guarantee identical outcomes for every patient. Some people respond strongly, others less so, and side effects, cost or limited availability can lead to treatment interruption. A systematic review and meta-analysis cited by Boaventura and Flint examined 37 studies involving 9,341 participants and found that weight regain after stopping obesity medication occurred faster than regain following behavioral weight-management programs, regardless of the amount of weight initially lost. The finding does not mean medication is ineffective; it shows why medication should be embedded in a plan designed for continuity and adaptation.

Behavior change is not a matter of receiving information and then demonstrating sufficient willpower. It emerges from the interaction of cognitive processes, emotions, motivation, self-regulation and the environment in which a person lives. An individual may intend to change eating patterns but face irregular work schedules, food insecurity, chronic stress, limited access to safe exercise spaces or a history of negative experiences in healthcare. Motivation itself can fluctuate, while habits are often triggered by cues that operate outside conscious awareness. Effective support therefore involves more than education. It can include collaborative goal setting, monitoring progress, identifying barriers, developing coping strategies, reinforcing self-efficacy and adjusting plans as circumstances change. Such interventions are most effective when they are person-centered: goals should reflect health, functioning and quality of life, not only the number on a scale. The authors say this broader approach is essential as drug-centered models become more common, because a prescription can influence appetite without supplying the skills and support needed to sustain health-related behaviors over years.

The commentary places weight stigma at the center of this challenge. People living with obesity frequently encounter moral judgment in clinics, workplaces, media and everyday life, where body size is often interpreted as evidence of laziness, irresponsibility or poor character. Those experiences can produce internalized weight stigma—the adoption of negative cultural beliefs about one’s own body—which is associated with distress, reduced self-confidence and disengagement from care. A clinical encounter that focuses narrowly on weight loss may unintentionally intensify the problem, particularly when treatment success is defined by a predetermined percentage of weight reduction. By contrast, addressing stigma and its consequences can improve eating self-efficacy, quality of life, treatment acceptability and patients’ ability to cope with difficult experiences. The authors argue that behavior-change support should therefore help people manage not only diet and physical activity, but also shame, discrimination, body-image concerns, fears of regain and the psychological burden of being judged.

The arrival of GLP-1 medications has produced a complicated cultural shift. On one hand, the drugs may challenge the idea that obesity is simply a failure of self-control by highlighting the roles of appetite, satiety, food reward and biological regulation. On the other hand, people who use them may still be criticized for taking what some regard as a shortcut. Research cited in the commentary suggests that GLP-1 use can influence how women with different body weights are evaluated, but the authors caution against assuming that medication automatically removes stigma. A person may lose weight and still carry years of negative self-beliefs, altered body image or anxiety about returning to a previous size. Physical change can itself require psychological adjustment, especially when identity, relationships and social treatment have been shaped by body weight. These consequences may persist even when a medication is working medically. In that sense, successful obesity care must address the lived experience of treatment rather than treating weight reduction as the sole endpoint.

Existing behavioral programs may not be broad enough for this new era. The intensive behavioral therapy model covered by the US Centers for Medicare & Medicaid Services emphasizes diet, physical activity and self-monitoring, with delivery largely centered on physicians and nurses and success commonly tied to weight-loss thresholds. Those components can be useful, but Boaventura and Flint argue that a weight-centered framework overlooks outcomes that matter to patients and health systems, including cardiometabolic health, mobility, mental well-being, quality of life and quality-adjusted life years. It may also fail to include professionals with specialized expertise in counseling, psychology, nutrition and sustained coaching. A broader model would measure whether people can maintain beneficial routines, manage distress, participate more fully in daily life and reduce health risks—even when weight loss is modest or fluctuates. This distinction is scientifically important because body weight is only one observable outcome of a treatment, while metabolic health and psychological functioning may change along different trajectories.

The risks become sharper when access to regulated care is limited. Demand, cost and shortages have encouraged some people to seek GLP-1 RAs through online sellers, private services or self-directed pathways. Such routes can separate medication access from clinical assessment, dose monitoring, side-effect management and follow-up. They may also expose patients to counterfeit or falsified products, inappropriate prescribing and fragmented care. When obtaining the drug becomes the primary objective, behavioral and psychosocial support can be treated as optional extras rather than essential parts of treatment. The authors do not suggest that every patient must receive an identical package of services, but they insist that safe care requires more than dispensing a medication. Patients need reliable information, supervision and access to appropriately trained professionals who can help them respond to changing appetite, adverse effects, treatment interruptions and the possibility of weight regain. Regulation, they argue, should focus not only on the products themselves but also on whether the surrounding service provides comprehensive care.

The policy implications extend beyond individual consultations. Multidisciplinary obesity treatment is widely recommended, yet it remains difficult to obtain in both public and private systems. Public-health programs need investment so that integrated services are available beyond specialist centers, while private care must confront the financial barriers created when several professionals and an expensive medication are combined. Health systems and regulators should ensure that obesity services include behavioral, psychological and social support, rather than allowing pharmacotherapy to become a substitute for chronic-care infrastructure. The authors describe this as an opportunity to redesign obesity treatment around empowerment and long-term health. GLP-1 RAs may be powerful tools, but they cannot by themselves teach people how to navigate stigma, stress, disrupted routines or the emotional consequences of bodily change. The future of obesity medicine, the commentary concludes, will be determined not simply by how many people receive these drugs, but by whether healthcare can surround them with the sustained, person-centered support required to make improvement safer and more durable.

Obesity and type 2 diabetes remain global health crises, burdening healthcare systems with escalating morbidity and mortality. Therapeutic strategies historically focused on single hormonal pathways, such as GLP-1 receptor agonists, have shown promise but often lack comprehensive metabolic control and cardiometabolic benefits. The development of multi-receptor agonists, including dual agonism of GLP-1R and GIPR, marked significant progress; however, significant unmet needs persist, particularly in overcoming obesity resistance and attenuating associated organ damage.

The recent preclinical study evaluated GLP-1–GIP–Lani, a conjugate peptide agonist that fuses dual incretin receptor activity with pan-PPAR targeting, in diet-induced obese (DIO) mice. This compound was administered daily via subcutaneous injection over an extended period. Striking weight loss was observed—surpassing that induced by co-administration of GLP-1–GIP with the PPAR-activating peptide lanifibranor. Importantly, weight reduction primarily stemmed from decreases in fat mass, while lean tissue mass was preserved, indicating selective adipose tissue targeting without muscle degradation.

Beyond weight management, GLP-1–GIP–Lani improved glucose homeostasis with superior glucose tolerance and insulin sensitivity relative to both vehicle controls and the comparator treatments. Consistent decreases in fasting blood glucose and plasma insulin concentrations highlighted its potent antihyperglycemic effects. These results underscore the compound’s ability to modulate pancreatic β-cell function and systemic insulin responsiveness effectively, crucial for halting diabetes progression.

Hepatic measurements revealed compelling benefits. GLP-1–GIP–Lani reduced liver weight and markedly diminished hepatic triglyceride accumulation, a hallmark of non-alcoholic fatty liver disease frequently accompanying obesity and diabetes. Biochemical liver injury markers, including plasma aspartate aminotransferase and alanine aminotransferase, were also reduced, suggesting hepatoprotective properties. Histological assessments confirmed the absence of adverse tissue alterations across the liver, skeletal muscle, heart, adipose tissue, and kidney, indicating a favorable safety profile.

Cardiac outcomes further distinguished GLP-1–GIP–Lani. In DIO mice, the quintuple agonist mitigated diet-induced cardiac hypertrophy, a condition contributing to heart failure risk. Functional cardiac parameters improved significantly, with increases in ejection fraction, fractional shortening, stroke volume, and cardiac output noted, coupled with a reduction in heart rate—all without deleterious changes in systemic blood pressure. This suggests enhanced cardiac efficiency and workload management in metabolically compromised states.

Renal safety, a critical consideration for metabolic drugs, was rigorously assessed. GLP-1–GIP–Lani administration did not provoke anemia, fluid retention, or alterations in creatinine concentrations in plasma or urine, indicating preserved renal function. These findings alleviate concerns about potential off-target renal side effects that have hampered the clinical translation of some metabolic agents.

A particularly striking finding was the compound’s efficacy in leptin receptor-deficient db/db mice, an obesity-prone model notoriously resistant to weight loss interventions including established drugs like tirzepatide and semaglutide. GLP-1–GIP–Lani fully prevented body weight gain and significantly outperformed the GLP-1–GIP plus lanifibranor co-treatment in reducing fat mass and food intake without lean mass compromise. Enhanced glucose regulation further validated its applicability in severe genetic obesity contexts.

This multifaceted therapeutic effect stems from the strategic polypharmacological approach that simultaneously manipulates incretin signaling and nuclear receptor pathways. GLP-1 and GIP receptor activation synergizes to optimize insulin secretion and appetite suppression, while pan-PPAR agonism modulates lipid metabolism, energy expenditure, and inflammation. This integrative mechanism addresses the complex pathophysiology of metabolic syndrome more effectively than receptor-selective agents.

The findings carry significant translational implications. GLP-1–GIP–Lani’s unique ability to induce sustained weight loss alongside robust glycemic control and organ protection without compromising lean mass or renal function may revolutionize treatment algorithms for obesity and type 2 diabetes. Future clinical studies will be pivotal to ascertain its safety and efficacy in humans, but the preclinical evidence offers a compelling rationale for rapid advancement.

Moreover, this study exemplifies the therapeutic promise of designing multifunctional agonists that integrate complementary receptor activities to overcome resistance mechanisms and enhance metabolic resilience. Such strategies hold potential not only for metabolic diseases but also for other complex disorders requiring concerted modulation of multiple pathways.

In conclusion, GLP-1–GIP–Lani epitomizes a next-generation polyagonist therapy that corrects obesity and diabetes in mouse models with exceptional potency and safety. By fostering weight loss, improving glucose metabolism, safeguarding liver function, enhancing cardiac performance, and preserving renal health, this quintuple agonist advances the frontier of metabolic therapeutics and offers hope for more effective clinical interventions.

Subject of Research:
Development and evaluation of a multi-receptor agonist (GLP-1R–GIPR–PPARα/γ/δ) for treating obesity and diabetes in mouse models.

Article Title:
GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice.

Article References:
Liskiewicz, D., Novikoff, A., Khalil, A. et al. GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice. Nature (2026). https://doi.org/10.1038/s41586-026-10427-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-026-10427-5